Description
This technology is a series of small molecule therapeutics to treat Henipavirus infections, which is a dangerous group of viruses that cause severe diseases in both humans and animals. These nanobodies are engineered to recognize and bind to specific proteins on Nipah and Hendra viruses, effectively cross-neutralizing different strains of Henipaviruses. Unlike traditional antibodies, nanobodies are smaller, more stable, and easier to produce, making them ideal therapeutic candidates. These molecules’ unique and novel structures allow them to bind tightly to specific targets on the Henipaviruses and enhance the efficacy of the treatments.
Henipaviruses have resulted in significant outbreaks across South Asia, Southeast Asia, and Australia. They are zoonotic pathogens with fatality rates of 50-100% for the most prominent forms (Nepah virus and Hendra virus), yet there are currently no approved vaccines or treatments available. As new strains of Henipavirus continue to emerge, the need for effective therapeutics has never been more urgent.
Benefits
Targeted Neutralization: Nanobodies specifically recognize and neutralize Henipaviruses, effectively preventing viral replication and spread.
Enhanced Stability and Production: Smaller and more stable than traditional antibodies, nanobodies can be produced in large quantities at a lower cost, ensuring quick availability during outbreaks.
Broad-spectrum: These compounds can cross-neutralize multiple strains of Henipaviruses, providing comprehensive protection and adaptability to evolving virus mutations.
Applications
Hendra Virus Therapeutics
Nipah Virus Therapeutics
Paramyxovirus Therapeutics
Patent Status
Pending
Publications